Baxter Supports New EFCNI Standards in Newborn Care in Raising Awareness of Risks from Malnutrition

  • The European Foundation for the Care of Newborn Infants (EFCNI)
    released new standards to address the disparities in newborn care
  • Preterm birth is one of the leading causes for neonatal mortality
    in Europe
    1
  • Nutritional care is a critical component of treating preterm
    neonates to optimize outcomes

BRUSSELS–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global leader in clinical
nutrition, is collaborating with the European Foundation for the Care of
Newborn Infants (EFCNI) to raise awareness for the new EFCNI standards
that address the disparities in newborn care in Europe. EFCNI released
the new
European Standards of Care for Newborn Health
last week.

These comprehensive standards provide research-backed protocols for key
elements of care, from birth to the neonatal intensive care unit (NICU)
stay to follow-up care. The standards are essential because preterm
birth is one of the leading causes for neonatal mortality in Europe and
accounts for more than half of all infant deaths.1 Worldwide,
more than 15 million infants are born preterm annually. 1

Preterm babies, and those born with illnesses, have special feeding
requirements during their hospital stays and after discharge. The
standards include several recommendations to help neonatologists improve
the nutritional care for preterm infants, including that NICUs establish
and implement site-specific nutrition guidelines. The goal is to ensure
that preterm infants receive adequate nutrients to promote proper
development and that clinicians monitor growth consistently.

The guidelines also outline that parenteral (intravenous) nutrition (PN)
be started on the first day after birth, usually using standard
solutions, such as premix solutions, and continued until sufficient
enteral feeding is established.

“As an innovator in clinical nutrition therapy, we are proud to support
and partner with EFCNI to raise awareness for better treatment standards
for the most vulnerable patient populations,” said Jorge Vasseur,
general manager of Baxter’s Clinical Nutrition business. “We will
continue our efforts to raise awareness on best practices for treating
preterm infants, while providing innovative nutritional therapies for
neonates.”

Baxter’s Numeta G13E is the only licensed, triple-chamber PN
product available to treat preterm infants (born before 37 weeks of
gestation) who are at high risk for infection and malnutrition in the
early hours and days of their lives. Premature infants are not usually
able to “suck and swallow” milk like full-term infants, and rely
entirely on PN to grow and develop. The data
released at the ISPOR Europe conference in Barcelona last month projects
that increasing use of standardized triple-chamber PN products like Numeta
G13E
compared to other PN preparation methods can help preterm
neonates by substantially reducing the risk of blood stream infections,
compounding errors and resource burdens associated with prematurity.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading
portfolio of critical care, nutrition, renal, hospital and surgical
products. For more than 85 years, we’ve been operating at the critical
intersection where innovations that save and sustain lives meet the
healthcare providers that make it happen. With products, technologies
and therapies available in more than 100 countries, Baxter’s employees
worldwide are now building upon the company’s rich heritage of medical
breakthroughs to advance the next generation of transformative
healthcare innovations. To learn more, visit www.baxter.com and
follow us on TwitterLinkedIn and Facebook.

IMPORTANT RISK INFORMATION

The general contraindications for administering Numeta as an
activated two-chamber container system (with the lipid chamber
inactivated for intravenous infusion) are as follows: hypersensitivity
to egg, soy or peanut proteins, or to any of the active substances,
excipients or components of the container; congenital abnormality of the
amino acid metabolism; pathologically elevated plasma concentrations of
sodium, potassium, magnesium, calcium and/or phosphorous; severe
hyperglycemia; and concomitant treatment with ceftriaxone in newborns
(<= 28 days of age), even if separate infusion lines are used.

The addition of lipids (administering Numeta as an activated
three-chamber container system for intravenous emulsion) is
contraindicated in the following additional clinical situations: severe
hyperlipidemia and severe disorders of lipid metabolism characterized by
hypertriglyceridemia. Refer to the Numeta product label for full
prescribing information.

This release includes forward-looking statements concerning Numeta
G13E
, including potential benefits associated with its use. The
statements are based on assumptions about many important factors,
including the following, which could cause actual results to differ
materially from those in the forward-looking statements: satisfaction of
regulatory and other requirements; actions of regulatory bodies and
other governmental authorities; product quality, manufacturing or
supply, or patient safety issues; changes in law and regulations; and
other risks identified in Baxter’s most recent filing on Form 10-K and
other SEC filings, all of which are available on Baxter’s website.
Baxter does not undertake to update its forward-looking statements.

Baxter and Numeta G13E are registered trademarks of Baxter
International Inc.

1 Althabe F, Howson CP, Kinney M, Lawn J, World Health
Organization. Born too soon: the global action report on preterm birth.
2012. Available from: www.who.int/pmnch/media/news/2012/201204_borntoosoon-report.pdf

Contacts

Media Contact
Beth Mueller, (224) 948-5353
media@baxter.com

Investor Contact
Clare Trachtman, (224) 948-3085